EN DE
Watch Actinium Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Actinium Pharmaceuticals Inc (ATNM) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Actinium Pharmaceuticals Inc stock $1.41, price $1.49, that is 5.4% below the price, quality 29 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AP Actinium Pharmaceuticals Inc logo Thin data Nov 17, 2026

Actinium Pharmaceuticals Inc

ATNM · US

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Highly profitable · 32.2% net margin (TTM) 
Ranks above peers (6/9) 
Costs just 4.1 times its yearly profit. 
Fair value $1.41 · Fairly valued 
Price moving sideways (no uptrend) 
Moderate moat 61/100 · thin data
Quality 29/100 
Weak Growth (revenue 5y −32.1 %/yr in USD) 
Negative free cash flow 
Recent news very negative 
Thin data 
Estimate
Watch Actinium Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.41 $0.7490 Fair Value $1.41 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.7490 – $14.41 · fair‑value band $1.06 – $1.77 · the $1.49 price screens above the $1.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Actinium Pharmaceuticals in your weekly email

Every Wednesday you see whether Actinium Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Show moreShow less

The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.

It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia.

Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.

The company is based in New York, New York.

Stock analysis

Actinium Pharmaceuticals Inc (ATNM) currently trades at $1.49, while our estimate is $1.41, so the stock looks roughly fairly valued today (gap 5.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.06 (bear) to $1.77 (bull), the price of $1.49 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Actinium Pharmaceuticals Inc reported revenue of $90.0K in FY2025 versus $1.1M in FY2021, a compound −47.0%/yr. Reported net income was −$33.9M in FY2025.

Key figures

Market cap $46.8M Micro · P/E ratio 4.1 · P/S ratio 1.33 · EPS (TTM) $0.3600 · Net margin 32.2% · Return on equity 45.9% · Return on assets (EBIT) −49.9% (5-year average) · Operating margin 27.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).

What moves the price

The share trades about 12% below its 52-week high and 99% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −5%, ATNM screens cheaper than that median.

Fair Value

Bear $1.06 Fair Value $1.41 Bull $1.77
Price $1.49 · Downside -5.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−55.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,600.2% (2020) → −40,274.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ATNM, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (77 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Actinium Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −5.4% · Top 25%
Profitability
Return on equity (12 months) 45.9% · Top 25%
Return on assets −65.5% · Bottom 25%
Net margin (12 months) 32.2% · Top 25%
Operating margin (12 months) 27.2% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 4.1× · Cheapest 25%
P/B 5.97× · Priciest 25%
P/S (12 months) 1.33× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)26 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ATNM
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ATNM
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs ATNM
argenx SE ARGX $950.95 $908.40 −4% vs ATNM
CSL Limited CSL A$199.55 A$186.49 −7% vs ATNM
Moderna, Inc MRNA $215.27 $135.64 −37% vs ATNM
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs ATNM
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ATNM
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs ATNM
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ATNM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Actinium Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Actinium Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/ATNM

Frequently asked questions

Is Actinium Pharmaceuticals Inc (ATNM) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $1.41 versus a price of $1.49, about 5% lower (fairly valued).
What is the fair value of ATNM?
Our estimate for Actinium Pharmaceuticals Inc is $1.41 (as of Nov 17, 2026), built from audited fundamentals. The current price: $1.49.
What is the quality score of ATNM?
Actinium Pharmaceuticals Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Actinium Pharmaceuticals Inc (ATNM)?
Our calculated price target is the estimate of $1.41 (as of Nov 17, 2026). Cautious scenario $1.06, optimistic scenario $1.77. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Actinium Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $1.41, about 5% lower versus a price of $1.49 (fairly valued). Cautious scenario $1.06, optimistic scenario $1.77. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Actinium Pharmaceuticals Inc (ATNM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Actinium Pharmaceuticals Inc it is $1.41 per share (as of Nov 17, 2026), against a price of $1.49.
Is Actinium Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, ATNM trades above its calculated fair value: price $1.49, fair value $1.41, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATNM?
No. The price is what the market pays today ($1.49); the fair value is what the company's own numbers justify ($1.41). For Actinium Pharmaceuticals Inc the two are $0.0800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Actinium Pharmaceuticals Inc worth?
The market values Actinium Pharmaceuticals Inc at about $46.8M (market capitalisation, as of Nov 17, 2026). Per share that is $1.49; our models calculate a fair value of $1.41 per share.
What do the bullish and bearish scenarios say about ATNM?
Our models span a range for Actinium Pharmaceuticals Inc: cautious scenario $1.06, base $1.41, optimistic $1.77 per share (as of Nov 17, 2026, price $1.49). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATNM?
Actinium Pharmaceuticals Inc trades at a price-to-earnings ratio of 4.1 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.41 is built from several models across several years. Other multiples: P/B 6.0, P/S 1.3.
How solid is the balance sheet of Actinium Pharmaceuticals Inc (ATNM)?
Balance-sheet figures for Actinium Pharmaceuticals Inc (as of Nov 17, 2026): return on equity 45.9%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is ATNM from its 52-week high?
Actinium Pharmaceuticals Inc trades at $1.49, about 12% below its 52-week high of $1.69 and 99% above the low of $0.7490 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.41 is for.
Which stocks are comparable to Actinium Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Actinium Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $1.49, calculated fair value $1.41 (−5%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Actinium Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Actinium Pharmaceuticals Inc (ATNM)?
The closing price on Nov 16, 2026 was $1.49. Our estimate is $1.41, about 5% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Actinium Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Actinium Pharmaceuticals Inc

How large is the market capitalisation of Actinium Pharmaceuticals Inc (ATNM)?
The market capitalisation of Actinium Pharmaceuticals Inc is $46.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Actinium Pharmaceuticals Inc (ATNM)?
The price-to-sales ratio of Actinium Pharmaceuticals Inc is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Actinium Pharmaceuticals Inc (ATNM)?
Earnings per share at Actinium Pharmaceuticals Inc are $0.3600 (price ÷ EPS = P/E 4.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Actinium Pharmaceuticals Inc (ATNM)?
The net margin of Actinium Pharmaceuticals Inc is 32.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Actinium Pharmaceuticals Inc (ATNM)?
The return on equity (ROE) of Actinium Pharmaceuticals Inc is 45.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Actinium Pharmaceuticals Inc (ATNM)?
On an EBIT basis the return on assets of Actinium Pharmaceuticals Inc is −49.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Actinium Pharmaceuticals Inc (ATNM)?
The operating margin of Actinium Pharmaceuticals Inc is 27.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Actinium Pharmaceuticals Inc (ATNM) generate?
The free cash flow of Actinium Pharmaceuticals Inc is −$24.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Actinium Pharmaceuticals Inc (ATNM) hold?
Actinium Pharmaceuticals Inc holds more cash than debt, $46.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Actinium Pharmaceuticals Inc in the live analysis

One click puts Actinium Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.